Court Rebuffs AstraZeneca’s Bid to Block FDA Approval of Generic Copies of Seroquel

In a ruling with huge potential financial implications for AstraZeneca, a District of Columbia federal court March 23 found that the drugmaker was not entitled to an injunction barring the Food and Drug Administration from approving competing generic versions of the drugmaker’s blockbuster antipsychotic drugs Seroquel and Seroquel XR (AstraZeneca Pharmaceuticals LP v. FDA, D.D.C., 1:12-cv-00388-CKK, 3/23/12).

Denying AstraZeneca’s application for a preliminary injunction and dismissing its lawsuit without prejudice, Judge Colleen Kollar-Kotelly of the U.S. District Court for the District of Columbia found that AstraZeneca “failed to make a clear showing that it is entitled to ...